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Abstract
Introduction Baroreflexes and peripheral chemoreflexes control efferent autonomic activity making these reflexes treatment 
targets for arterial hypertension. The literature on their interaction is controversial, with suggestions that their individual and 
collective influence on blood pressure and heart rate regulation is variable. Therefore, we applied a study design that allows 
the elucidation of individual baroreflex–chemoreflex interactions.
Methods We studied nine healthy young men who breathed either normal air (normoxia) or an air–nitrogen–carbon diox-
ide mixture with decreased oxygen content (hypoxia) for 90 min, with randomization to condition, followed by a 30-min 
recovery period and  then exposure to the other condition for 90 min. Multiple intravenous phenylephrine bolus doses  were 
applied per condition to determine phenylephrine pressor sensitivity as an estimate of baroreflex blood pressure buffering 
and cardiovagal baroreflex sensitivity (BRS).
Results Hypoxia reduced arterial oxygen saturation from 98.1 ± 0.4 to 81.0 ± 0.4% (p < 0.001), raised heart rate from 
62.9 ± 2.1 to 76.0 ± 3.6 bpm (p < 0.001), but did not change systolic blood pressure (p = 0.182).  Of the nine subjects, six 
had significantly lower BRS in hypoxia (p < 0.05), two showed a significantly decreased pressor response, and three showed 
a significantly increased pressor response to phenylephrine in hypoxia, likely through reduced baroreflex buffering (p < 0.05). 
On average, hypoxia decreased BRS by 6.4 ± 0.9 ms/mmHg (19.9 ± 2.0 vs. 14.12 ± 1.6 ms/mmHg; p < 0.001) but did not 
change the phenylephrine pressor response (p = 0.878).
Conclusion We applied an approach to assess individual baroreflex–chemoreflex interactions in human subjects. A subgroup 
exhibited significant impairments in baroreflex blood pressure buffering and BRS with peripheral chemoreflex activation. The 
methodology may have utility in elucidating individual pathophysiology and in targeting treatments modulating baroreflex 
or chemoreflex function.
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Introduction
Arterial baroreflexes and peripheral chemoreflexes have 
been implicated in the pathogenesis of arterial hyperten-
sion and identified as treatment targets [1]. Both originate 
from receptors, namely, the carotid sinus baroreceptors 
and carotid body chemoreceptors, respectively, located in 
close proximity to the carotid bifurcation  [2, 3]. Barore-
flexes buffer changes in blood pressure through counter-
regulatory adjustments in efferent sympathetic and para-
sympathetic activity and affect long-term blood pressure 
control [4], and carotid body chemoreceptor stimulation 
raises sympathetic activity [5]. In arterial hypertension, 
the sympathetic baroreflex gain is depressed and the 
baroreflex is reset to higher blood pressure [6]; in con-
trast, carotid chemoreceptors are sensitized [7–9] and gen-
erate tonic sympathetic activation [10–13] in hypertensive 
patients. Baroreceptor and carotid body afferents converge 
onto neurons in the dorsomedial medulla [14], resulting in 
an inhibitory interaction [15, 16]. Thus, impaired barore-
flex regulation in arterial hypertension may be mediated 
in part through inappropriate carotid body chemoreceptor 
activation [1, 9]. Electrical carotid sinus stimulators and 
stents augmenting baroreceptor transmission as well as 
peripheral chemoreceptor modulation have been developed 
for hypertension management; however, all baroreceptor 
reflex modulation procedures developed to date exhibit an 
unacceptably high proportion of non-responders [17–20]. 
Blood pressure reductions following such interventions 
are likely determined by interindividual differences 
in baroreflex–chemoreflex interactions, which are not 
uncovered through routine clinical testing. While human 
baroreflex–chemoreflex interactions have been previously 
investigated [16, 21, 22], we hypothesized that a combi-
nation of physiological profiling and multiple repeated 
measurements could be utilized to elucidate individual 
baroreflex–chemoreflex interactions. In our study, hypoxia 
served as the peripheral chemoreceptor stimulus. In a simi-
lar fashion, patients have been repeatedly exposed to test 
and control interventions, such as statin and placebo treat-
ment, to elucidate individual responses in so-called N-of-
one trials [23, 24].
Methods
Subjects
Nine healthy young men with a mean age of 28.8 ± 3.0 years 
and  a mean body mass index of 23.8 ± 0.8 kg/m2 were 
enrolled in the study (Table 1). Medical history and results 
from the physical examination, resting electrocardiogram, 
spirometry, and routine blood testing were all in the normal 
range. The ethics committee of the North Rhine medical 
association approved the study, and the study was registered 
in the German Clinical Trials register (DRKS00013101). 
Written informed consent was obtained from each partici-
pant before study entry.
Protocol
All measurements were obtained with the subjects in the 
supine position after they had voided their bladder. We 
assessed non-invasive beat-to-beat blood pressure (Finap-
res® NOVA; Finapres Medical Systems, Enschede, The 
Netherlands), upper arm blood pressure, arterial oxygen 
saturation, end-tidal carbon dioxide  (ETCO2) concentra-
tion, breathing frequency, tidal volume, minute ventilation 
(Innocor; Innovision, Odense, Denmark), and an electro-
cardiogram recording (Vital Guard 450C; Ivy Biomedical 
Systems, Inc., Branford, CT, USA). An antecubital venous 
catheter was set in place for drug administration. Baseline 
data were recorded for 10 min prior to starting the rand-
omized protocol (Table 1).
Table 1  Baseline characteristics 
of subjects (n = 9)
Values in table are the baseline characteristics of each subject taken before the beginning of the first session
SBP Systolic blood pressure, DBP diastolic blood pressure, HR heart rate, BMI body mass index
Subject SBP (mmHg) DBP (mmHg) HR (bpm) BMI (kg/m2) Age (years)
01 126 78 61 27.4 37
02 136 78 61 24.5 30
03 122 74 65 22.6 24
04 132 82 66 24.5 38
05 136 70 67 24.2 20
06 125 80 79 21.2 22
07 139 82 48 24.3 34
08 127 62 80 20.8 24
09 127 72 55 22.6 33
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We first determined the individual dose of the alpha-
1-adrenoreceptor agonist phenylephrine that was needed 
to raise to blood pressure by 20–30 mmHg, using incre-
mental doses of between 25 and 100 µg. All phenylephrine 
doses were immediately followed by a 10-ml saline flush. 
Both procedures were conducted in a standardized fash-
ion using an automated bolus injector (Accutron MR; 
Medtron AG, Saarbrücken, Germany). Bolus flow rates 
were 5 ml/s for phenylephrine and 2.5 ml/s for the saline 
bolus, resulting in administration durations of 4.1–4.4 
s. Following determination of the appropriate dose, we 
obtained repeated baroreflex measurements using the pre-
determined phenylephrine dose, with the subjects exposed 
to either the normoxic or hypoxic condition for 90 min, 
with randomization to one or the other condition and 
single blinding (subjects). Following the first exposure, 
subjects were allowed to recover for 30 min during which 
time they could stand up and empty their bladder, with the 
aim to minimize any carry-over effects from being supine 
or hypoxic, before being exposed for 90 min to the other 
condition.  In the first 10 min of each exposure, inspiratory 
oxygen was slowly lowered to attain hypoxia or kept con-
stant for normoxia testing. Thereafter, 20 phenylephrine 
bolus doses were applied, one every 4 min. The study pro-
tocol is illustrated in Fig. 1.
Hypoxic peripheral chemoreflex stimulation
We utilized a hypoxic gas mixture containing nitrogen, 
oxygen, and carbon dioxide. Compressed air and nitro-
gen were mixed in a blender (Bird™ Blender low flow; 
Vyaire Medical Inc., Mettawa, IL, USA). Carbon dioxide 
was added separately in order to maintain normocapnia. 
Gas flows were controlled using flowmeters and buffered 
in a Douglas bag from which the subject could inhale with-
out resistance or pressure via a face mask. For normocap-
nic hypoxia, the target was 80% arterial oxygen satura-
tion, achieved by manual adjustment. To keep subjects 
blind to the condition, the same toolset was used to apply 
compressed air during both the hypoxia and normoxia 
procedures.
Baroreflex measurements
Two parameters that characterize baroreflex function were 
assessed, namely, cardiovagal baroreflex sensitivity (BRS) 
and baroreflex buffering capacity. For both measurements 
we utilized the increase in finger blood pressure after the 
administration of each phenylephrine bolus. This pharmaco-
logical approach ensures greater independence from ventila-
tory influences on baroreflex function than methods based 
on spontaneous variations in hemodynamic variables. The 
investigator was blinded to the condition, i.e., normoxia or 
hypoxia.
1. Cardiovagal BRS was assessed as the slope of the 
regression line between each systolic blood pressure 
(SBP) value and the following RR interval during the 
phenylephrine-induced pressure rise without an offset 
[25, 26]. The slope was accepted if Pearson’s correlation 
coefficient r > 0.5 [27].
2. Larger increases in blood pressure after the administra-
tion of a defined phenylephrine bolus denote reduced the 
baroreflex buffering capacity. We determined this phe-
nylephrine sensitivity as rise in SBP (ΔSBP) from the 
baseline before each bolus to the SBP maximum after 
bolus application [28]. Baseline SBP was calculated by 
averaging ten readings taken before each bolus. Maxi-
mum SBP was obtained by averaging the three highest 
consecutive SBP values within 60 s after each bolus.
Statistics
Individual BRS and phenylephrine responses were ana-
lyzed using unpaired t tests. For group comparisons, we 
used medians of up to 20 boli per condition in order to 
minimize the effect of possible outliers and analyzed these 
via the paired t test. Significance was assumed at p < 0.05. 
If not otherwise indicated, all values were expressed as 
the mean ± SE. Power for BRS and change in SBP were 
Fig. 1  Schematic illustration 
of the study protocol. Phe Phe-
nylephrine
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calculated post hoc by means of the statistical analysis tool 
G*Power 3.1. We estimated the number of bolus repetitions 
needed to estimate individual effects between normoxia and 
hypoxia with receiver operating characteristic curve analysis 
performed with SPSS V.21 software (IBM Corp., Armonk, 
NY, USA). All other statistical analyses were done using 
Graphpad Prism 7.04 (GraphPad Software Inc., San Diego, 
CA, USA)
Results
All subjects tolerated baroreflex testing in both normoxia 
and hypoxia, and no adverse events were observed. Arte-
rial oxygen saturation was 98.1 ± 0.4% during normoxia 
and 81.0 ± 0.4% during hypoxia (p < 0.001), and  ETCO2 
remained at baseline values (38.31 ± 0.9 [normoxia] vs. 
37.78 ± 1.1 mmHg [hypoxia]; p = 0.245).  Respiratory rate 
(16 ± 1 vs. 16 ± 1/min; p = 0.588) did not change.  Dur-
ing hypoxia, tidal volume increased from 0.77 ± 0.04 to 
0.95 ± 0.07 l (p = 0.002), and minute ventilation increased 
from 11.86 ± 0.51 to 13.95 ± 0.49  l/min (p = 0.036); the 
mean respiratory chemoreflex response (ΔVe/SpO2) was 
11.79 ± 4.80 (l/min)/%.
Blood pressure was 133 ± 3/76 ± 2 mmHg during nor-
moxia and 135 ± 3/76 ± 2 mmHg during hypoxia. During 
the experiment systolic blood pressure ranged from 122 to 
154 mmHg during normoxia and from 121 to 148 mmHg 
during hypoxia. Heart rate increased from 63 ± 2 bpm during 
normoxia to 76 ± 4 bpm during hypoxia (p < 0.001). Figure 2 
illustrates original blood pressure and RR-interval responses 
to repeated phenylephrine doses during normoxia and during 
hypoxia in one subject.
Individual baroreflex responses are given in Tables 2, 
3, and Fig. 3. Not all phenylephrine applications yielded 
responses suitable for baroreflex analysis. The number of 
bolus doses analyzed for each subject and condition ranged 
between 8 and 20 (Tables 2, 3). In hypoxia, BRS was sig-
nificantly lowered in six subjects; Figure 3a illustrates indi-
vidual changes in BRS, including the 95% confidence inter-
vals, with reductions in BRS during hypoxia in these six 
subjects. Overall BRS decreased from 19.9 ± 2.0 ms/mmHg 
in normoxia to 14.1 ± 1.6 ms/mmHg in hypoxia (p < 0.001; 
power 0.995; Fig. 3a).
Five subjects showed a significant change in phenyle-
phrine responsiveness with hypoxic peripheral chemoreflex 
stimulation (Table 3), with phenylephrine responsiveness 
significantly decreasing in two subjects and significantly 
increasing in three subjects. In the other four subjects, phe-
nylephrine sensitivity did not change significantly. Overall, 
phenylephrine responsiveness did not change (p = 0.878), 
as shown in Fig.  3b, which plots individual changes in 
phenylephrine sensitivity, including the 95% confidence 
intervals, and indicates the high interindividual variability.
The optimal number of repetitions for individual BRS 
changes was ten  boli with a sensitivity of 0.96. This is 
derived from our heathy subjects with an effect size of 
6 ± 3 ms/mmHg (difference in BRS between normoxia and 
hypoxia).Overall, we did not observe a linear correlation 
between changes in BRS or phenylephrine responsiveness 
and respiratory parameters (respiratory rate, tidal volume, 
or minute ventilation). Individual respiratory parameters 
varied, as shown in Table 4.
Hemodynamic reactions were stable over time during 
normoxia and hypoxia (Fig. 2). The sequence of the condi-
tions normoxia and hypoxia did not affect BRS or phenyle-
phrine responsiveness measurements.
We could not find a correlation between changes in car-
diac BRS and baroreflex buffering capacity (Fig. 4).
Discussion
In the study reported here, we applied a novel approach to 
elucidate individual baroreflex–chemoreflex interactions 
using repeated administrations of a standardized phenyle-
phrine bolus during normoxia and hypoxia. While individual 
and group cardiovagal BRS responses to hypoxic periph-
eral chemoreceptor stimulation showed similar qualitative 
responses, individual responses exhibited substantial quan-
titative variability. Strikingly, individual phenylephrine 
responsiveness revealed qualitatively different responses, 
possibly resulting from changes in vascular sensitivity, in 
baroreflex blood pressure buffering, or in both mechanisms 
combined [28]. Our findings provide insight into human 
autonomic cardiovascular control mechanisms and could 
be useful in individualized assessment of baroreflex–chem-
oreflex interactions in patients with arterial hypertension, 
particularly in those considered for interventions targeting 
these reflexes.
The highly standardized assessment of baroreflex func-
tion using phenylephrine doses applied through an auto-
mated injector is a particular strength of our study. In previ-
ous studies, vasoactive drugs for baroreflex testing as well 
as subsequent saline flushes were manually applied [21, 29]. 
The lack of standardization likely introduces variability in 
drug delivery, immediate vascular responses, and subse-
quent baroreflex counter regulation. Our approach reduced 
this variability source. Another strength of our study is the 
large number of repeated phenylephrine tests which, unlike 
in previous studies, allowed for individual assessment of the 
baroreflex–chemoreflex interaction. We found that ten boli 
with a significant cardiovagal baroreflex response could be 
the appropriate number of boli for an optimal estimation 
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Fig. 2  Original recording of RR-interval (RRI) and systolic blood 
pressure (SBP) responses to phenylephrine boli given during nor-
moxia (a) and hypoxia (b), as well as corresponding peripheral cap-
illary oxygen saturation (SpO2) curves (c). a, b Black arrows show 
timepoints at which phenylephrine boli were injected; the black upper 
lines correspond to RRI with the RRI axis on the left, and the lower 
gray lines correspond to SBP with the axis on the right side
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Table 2  Individual baroreflex responses of the nine subjects in normoxia and hypoxia
BRS Baroreflex sensitivity
BRS values are presented as the  individual mean values ± standard error of the mean (SEM), together with the corresponding number of boli
p values and t correspond to measurements in normoxia vs. those in  hypoxia. Significance was assumed at p < 0.05
Subject Order of condition applied 
(condition applied first)
Normoxia Hypoxia Statistical analysis
BRS (ms/mmHg) Boli (n) BRS (ms/mmHg) boli (n) p value t
01 Hypoxia 19.6 ± 2.1 17 18.3 ± 1.4 19 0.603 0.525
02 Normoxia 14.9 ± 1.4 16 9.5 ± 1.4 17 0.011 2.689
03 Hypoxia 18.9 ± 1.9 18 11.4 ± 1.2 17 0.002 3.307
04 Normoxia 14.4 ± 1.2 19 11.1 ± 2.1 17 0.159 1.439
05 Normoxia 29.0 ± 2.0 14 19.6 ± 1.9 16 0.002 3.381
06 Hypoxia 14.7 ± 1.2 16 10.1 ± 0.9 17 0.017 2.533
07 Normoxia 28.6 ± 3.3 16 16.8 ± 2.6 8 0.028 2.35
08 Hypoxia 14.4 ± 0.8 20 8.3 ± 0.8 20  < 0.001 5.399
09 Hypoxia 24.9 ± 1.6 19 21.1 ± 1.8 17 0.122 1.585
Table 3  Change in systolic 
blood pressure in normoxia and 
hypoxia in the nine subjects
ΔSBP values are presented as individual mean values ±  SEM, together with the corresponding number of 
boli
p values and t correspond to measurements in normoxia vs. those in  hypoxia. Significance was assumed at 
p < 0.05
Subject Order of condition 
applied (condition 
applied first)
Normoxia Hypoxia Statistical 
analysis
ΔSBP (mmHg) Boli (n) ΔSBP (mmHg) Boli (n) p value t
01 Hypoxia 17.6 ± 1.2 20 21.8 ± 1.4 20 0.026 2.31
02 Normoxia 25.7 ± 2.7 20 23.2 ± 2.9 17 0.531 0.633
03 Hypoxia 27.8 ± 1.1 20 31.0 ± 2.4 20 0.232 1.214
04 Normoxia 19.4 ± 1.7 19 29.7 ± 2.3 18 0.001 3.576
05 Normoxia 18.1 ± 1.6 19 24.1 ± 2.2 20 0.033 2.21
06 Hypoxia 30.0 ± 1.7 20 26.0 ± 2.0 20 0.1396 1.509
07 Normoxia 17.1 ± 1.8 20 13.0 ± 1.4 20 0.069 1.872
08 Hypoxia 30.3 ± 1.3 20 22.2 ± 1.1 20 < 0.001 4.714
09 Hypoxia 19.1 ± 1.2 20 12.5 ± 1.9 20 0.006 2.943
Fig. 3  Forest plots of individual 
changes (hypoxia–normoxia) in 
cardiovagal baroreflex sensitiv-
ity (BRS) (a) and individual 
changes in phenylephrine sensi-
tivity (b). Data points indicate 
mean difference in BRS or 
SBP increase between hypoxia 
and normoxia, and error bars 
indicate the range of these dif-
ferences (95% confidence inter-
val). p values are shown next to 
each data point, and asterisks, 
where present, indicate signifi-
cance of difference (*p < 0.05; 
**p < 0.01; ***p < 0.001)
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of individual BRS changes induced by hypoxic peripheral 
chemoreceptor activation in the clinical setting.
We observed complex changes in baroreflex regulation 
with hypoxic peripheral chemoreflex stimulation. Average 
blood pressure was unchanged while the heart rate increased 
substantially. The baroreflex heart rate/pressure relation-
ship was shifted towards higher heart rates and cardiovagal 
BRS was reduced. Increases in heart rate and maintained 
or increased blood pressure with peripheral chemoreflex 
stimulation have been previously described; in these studies 
sympathetic and parasympathetic baroreflex gains [21, 22, 
30, 31] and baroreflex responsiveness [32] did not change. 
However, in two studies, chemoreflex-induced resetting 
of baroreflex-mediated sympathetic vasomotor control to 
higher blood pressure levels was observed using spontaneous 
baroreflex threshold [21] and modified Oxford techniques 
[29]. We speculate that the discrepancy in cardiovagal BRS 
responses may result in part from the methodology to assess 
baroreflex function or the high variability which we reduced 
through repeated testing. Interindividual and between-study 
variability in the BRS response to hypoxic chemoreceptor 
stimulation may partly result from variability in chemosen-
sitivity [33].
Baroreflex regulation of sympathetic traffic to the vas-
culature is particularly relevant for blood pressure control. 
However, direct sympathetic nerve recordings are available 
in only a few medical centers and the tests often fail for 
technical reasons. As an alternative, the primary function 
of the baroreflex, which is to buffer blood pressure changes, 
can be assessed by applying vasoactive drugs before and 
during complete interruption of the baroreflex arc through 
ganglionic blockade [28]; the sensitivity to vasoactive drugs 
changes less in individuals with less efficient baroreflex 
blood pressure buffering than in those with more efficient 
baroreflex blood pressure buffering. Influences of gender, 
age, autonomic failure, and arterial hypertension on blood 
pressure buffering have been previously assessed [34–36]. 
Ganglionic blockers are no longer available for investiga-
tions on humans, and the methodology is cumbersome. 
Approximately 80% of the variability in systemic phenyle-
phrine pressor sensitivity can be attributed to variability in 
baroreflex buffering rather than to vascular responsiveness 
[28]. That analysis included healthy persons and patients 
with various disorders known to affect vascular alpha-
adrenoreceptor responsiveness. Therefore, phenylephrine 
responses without ganglionic blockade may provide an esti-
mate of baroreflex buffering capacity. Thus, the results of 
our study may suggest that there is a dissociation between 
cardiovagal BRS and baroreflex blood pressure buffering 
during hypoxic chemoreflex stimulation.
The major limitation of our study is that findings in 
healthy subjects cannot be simply extrapolated to patients 
Table 4  Respiration parameters recorded for each of the nine subjects throughout each session in normoxia or hypoxia
Ve Minute ventilation, SpO2 peripheral capillary oxygen saturation, ΔVe/ ΔSpO2 mean respiratory chemoreflex response
Where appropriate, values are given as the mean ±  SEM
Subject Respiratory rate (breaths/min) Tidal volume (l) Minute ventilation (l/min) ΔSpO2 (%) ΔVe/ 
ΔSpO22 ([l/
min]/%)Normoxia Hypoxia Normoxia Hypoxia Normoxia Hypoxia
01 9.53 ± 0.10 13.04 ± 0.08 1.05 ± 0.02 1.33 ± 0.01 9.33 ± 0.12 16.86 ± 0.11 17.30 43.53
02 17.11 ± 0.05 17.95 ± 0.13 0.80 ± 0.00 0.88 ± 0.01 13.64 ± 0.06 15.67 ± 0.15 18.51 11.11
03 14.13 ± 0.11 12.55 ± 0.16 0.87 ± 0.01 1.13 ± 0.02 11.62 ± 0.09 12.48 ± 0.14 16.53 5.25
04 16.30 ± 0.09 16.02 ± 0.09 0.73 ± 0.01 0.83 ± 0.01 11.64 ± 0.05 12.77 ± 0.10 16.40 6.91
05 19.12 ± 0.08 20.26 ± 0.08 0.69 ± 0.01 0.73 ± 0.01 12.53 ± 0.07 14.13 ± 0.08 16.86 9.48
06 19.13 ± 0.08 17.36 ± 0.12 0.73 ± 0.01 0.76 ± 0.01 13.66 ± 0.05 12.50 ± 0.09 15.29 − 7.57
07 18.89 ± 0.09 14.09 ± 0.13 0.74 ± 0.01 1.04 ± 0.02 13.17 ± 0.08 13.52 ± 0.20 16.89 2.05
08 18.29 ± 0.07 18.3 ± 0.09 0.62 ± 0.00 0.77 ± 0.00 11.13 ± 0.03 13.64 ± 0.05 19.03 13.20
09 14.15 ± 0.08 13.19 ± 0.08 0.72 ± 0.00 1.07 ± 0.01 10.02 ± 0.06 13.94 ± 0.08 17.74 22.11
Fig. 4  Correlation analysis between changes in cardiovagal baroreflex 
sensitivity and phenylephrine sensitivity. Phenylephrine sensitivity 
is considered as a marker of baroreflex-mediated buffering of blood 
pressure
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with arterial hypertension, particularly those considered 
for device-based treatments targeting the baroreflex or 
peripheral chemoreceptors. The fact that we did not assess 
sympathetic nerve activity is another potential limitation. 
Moreover, we determined an estimate of baroreflex blood 
pressure buffering rather than making a comparison phe-
nylephrine responses before and after ganglionic block-
ade for the reasons mentioned above. While much of the 
interindividual variability in phenylephrine responsiveness 
can be explained by baroreflex blood pressure buffering, 
hypoxia-induced changes in vascular alpha-adrenorecep-
tor responsiveness may have confounded the analysis. 
However, data from human [37] and animal studies [38] 
regarding direct vascular actions of hypoxia are contro-
versial, and it is evident that changes in vascular tone 
during hypoxia cannot be solely explained by baroreflex-
mediated changes in adrenergic drive. Our observed BRS 
and phenylephrine responsiveness shift with hypoxia may 
be the result of hypoxia-induced vasodilation [39, 40]. 
Furthermore, hypoxia-induced heart rate changes are not 
abolished following bilateral carotid body removal [41]. 
However, in patients with resistant arterial hypertension, 
reductions in sympathetic traffic and blood pressure with 
electrical carotid sinus stimulation were found to be virtu-
ally identical with and without hypoxia [42]. This obser-
vation excludes major changes in the coupling between 
sympathetic activity and vasoconstriction with hypoxia. 
 ETCO2, which affects cardiovascular control, was kept 
constant during our study. While we applied hypoxia in a 
steady-state fashion, transient hypoxia has been proposed 
to provide a more selective peripheral chemoreceptor stim-
ulus [43]. Finally, hypoxia may have a prolonged effect 
on sympathetic activity [44]—although the sequence of 
normoxia and hypoxia sessions in our study did not affect 
our results. Moreover, we did not observe a substantial 
sustained effect of hypoxia on sympathetic activity or the 
response to electrical carotid sinus stimulation in patients 
with treatment-resistant arterial hypertension [42].
Despite these limitations, our study suggests that interin-
dividual variability of baroreflex and chemoreflex regulation 
is so high that treatments modulating these mechanisms are 
exceedingly unlikely to be equally effective in all patients. In 
recent years there has been a thrust towards precision medi-
cine [45]. Usually, the term implicates molecular assessment 
of a disease trait, such as somatic mutations in a specific can-
cer, that results in a targeted intervention. Outside oncology, 
the merits of the approach in common conditions, including 
arterial hypertension, have been limited; indeed, molecu-
lar signatures guiding hypertension treatment do not exist. 
However, individual physiological profiling could be utilized 
to identify underlying mechanisms driving hypertension and 
to direct treatments to patients more likely to respond. Our 
study suggests that repeated phenylephrine testing during 
normoxia and during hypoxia deserves to be tested in this 
setting.
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